Intensification phase and myeloablative chemotherapy
| . | Drug/dose/administration schedule . |
|---|---|
| Intensification | |
| 1° and 4° week | One or 2 courses of R-IVAC or R-ICE (debulking chemotherapy) |
| 7° to 8° week | Cyclophosphamide 4 g/m2 |
| Rituximab 375 mg/m2 on days 3 and 10 | |
| In vivo–purged PBPC collection (day 11-13) | |
| 11° to 12° week | Cytarabine 2 g/m2 every 12 h for 4 days (days −5 to −2) |
| Rituximab 375 mg/m2 (day −1 and +11) | |
| Second in vivo–purged PBPC collection (only if needed) | |
| BEAM regimen | |
| Day 1 | Carmustine∗ 300 mg/m2 |
| Days 2-5 | Etoposide 100 mg/m2 every 12 h |
| Cytarabine 200 mg/m2 every 12 h | |
| Day 6 | Melphalan 140 mg/m2 |
| Day 8 | Reinfusion of ≥ 5 × 106 CD34+ cells per kg body weight |
| . | Drug/dose/administration schedule . |
|---|---|
| Intensification | |
| 1° and 4° week | One or 2 courses of R-IVAC or R-ICE (debulking chemotherapy) |
| 7° to 8° week | Cyclophosphamide 4 g/m2 |
| Rituximab 375 mg/m2 on days 3 and 10 | |
| In vivo–purged PBPC collection (day 11-13) | |
| 11° to 12° week | Cytarabine 2 g/m2 every 12 h for 4 days (days −5 to −2) |
| Rituximab 375 mg/m2 (day −1 and +11) | |
| Second in vivo–purged PBPC collection (only if needed) | |
| BEAM regimen | |
| Day 1 | Carmustine∗ 300 mg/m2 |
| Days 2-5 | Etoposide 100 mg/m2 every 12 h |
| Cytarabine 200 mg/m2 every 12 h | |
| Day 6 | Melphalan 140 mg/m2 |
| Day 8 | Reinfusion of ≥ 5 × 106 CD34+ cells per kg body weight |
BEAM, XXX; R-ICE, rituximab, ifosfamide, carboplatin, etoposide; R-IVAC, rituximab, ifosfamide, etoposide, cytarabine, cyclophosphamide; PBPC, peripheral blood progenitor cells.
When it was not available, carmustine was replaced by fotemustine 150 mg/m2 per day days 1 and 2 (FEAM [fotemustine, etoposide, cytaraine, melfalan] regimen).